Please ensure Javascript is enabled for purposes of website accessibility

FDA Warns Companies Selling Fraudulent COVID-19 Products

By David Jagielski - Updated Mar 9, 2020 at 1:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA hasn't approved any drugs to treat COVID-19 although many companies continue working on vaccines and treatment options.

The Food and Drug Administration (FDA) announced on Monday that it sent warning letters to seven companies for selling unapproved drugs. The FDA says these products "pose significant risks to patient health" as they claim to either treat or prevent COVID-19.

However, the FDA is ready to go beyond issuing warning letters. FTC Chairman Joe Simons said in the release, "What we don't need in this situation are companies preying on consumers by promoting products with fraudulent prevention and treatment claims. These warning letters are just the first step. We're prepared to take enforcement actions against companies that continue to market this type of scam." One recipient of a warning letter is televangelist Jim Bakker who is selling a silver solution, purporting to be a treatment for coronavirus.

As of its update on March 8, the World Health Organization (WHO) said there are more than 105,000 cases of COVID-19 around the globe. The risk assessment remains "very high" as the disease has spread to dozens of countries, sending not just consumers but investors into a panic. The S&P 500 was down more than 11% heading into trading on Monday, triggering the employment of circuit breakers to halt trading temporarily

Woman wearing surgical mask.

Image source: Getty Images.

Gilead continues to test remdesivir

Currently, there's no cure or approved treatment for COVID-19. However, Gilead Sciences(GILD -0.40%) remdesivir drug has shown signs of progress and it could aid in treating patients with the disease. On Feb. 26, the company announced it had begun two phase 3 studies on remdesivir that will test the drug's safety and effectiveness on approximately 1,000 patients.

Other healthcare stocks are trying to develop drugs for COVID-19 but Gilead's remdesivir drug has been one singled out by the WHO as showing the most potential. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.83 (-0.40%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.